We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-4.03%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$307M
AUM Growth
+$22M
Cap. Flow
+$44.8M
Cap. Flow %
14.59%
Top 10 Hldgs %
56.38%
Holding
71
New
21
Increased
13
Reduced
13
Closed
22

Top Buys

Rank Stock Value
1
TAK icon
Takeda Pharmaceutical
TAK
+$15.3M
2
LH icon
Labcorp
LH
+$14.9M
3
CTLT
CATALENT, INC.
CTLT
+$13.9M
4
LLY icon
Eli Lilly
LLY
+$12.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.5M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$15.6M
2
AVTR icon
Avantor
AVTR
+$10M
3
HOLX
Hologic
HOLX
+$8.85M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$5.82M
5
CNC icon
Centene
CNC
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 77.14%
2 Real Estate 4.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MMSI icon
26
Merit Medical Systems
MMSI
$5.26B
$2.89M 0.94%
51,218
+30,995
+153% +$1.79M
RCUS icon
27
Arcus Biosciences
RCUS
$3.48B
$2.55M 0.83%
97,327
+32,571
+50% +$861K
INSM icon
28
Insmed
INSM
$28.5B
$2.32M 0.76%
107,713
-34,358
-24% -$824K
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.7B
$2.17M 0.71%
50,822
-588
-1% -$30.1K
ADAP
30
DELISTED
Adaptimmune Therapeutics
ADAP
$1.92M 0.63%
1,788,517
-35,548
-2% -$65.3K
CANO
31
DELISTED
Cano Health, Inc.
CANO
$1.83M 0.6%
+2,109
New +$1.32M
VCYT icon
32
Veracyte
VCYT
$3.7B
$1.8M 0.59%
+108,751
New +$2.45M
AVTR icon
33
Avantor
AVTR
$8.91B
$1.49M 0.48%
75,948
-374,873
-83% -$10M
STRO icon
34
Sutro Biopharma
STRO
$405M
$1.48M 0.48%
26,668
-9,079
-25% -$537K
TEVA icon
35
Teva Pharmaceuticals
TEVA
$40.2B
$1.45M 0.47%
179,226
-280,603
-61% -$2.48M
OPCH icon
36
Option Care Health
OPCH
$3.52B
$1.37M 0.45%
+43,457
New +$1.39M
ACH
37
Accendra Health
ACH
$229M
$1.35M 0.44%
+55,914
New +$1.72M
PCVX icon
38
Vaxcyte
PCVX
$8.38B
$1.25M 0.41%
+52,309
New +$1.33M
RETA
39
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$612K 0.2%
+24,352
New +$675K
MRVI icon
40
Maravai LifeSciences
MRVI
$916M
$580K 0.19%
22,709
-306
-1% -$7.68K
ABOS icon
41
Acumen Pharmaceuticals
ABOS
$163M
$555K 0.18%
+55,328
New +$317K
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$553K 0.18%
+7,915
New +$586K
RLMD icon
43
Relmada Therapeutics
RLMD
$567M
$524K 0.17%
+14,145
New +$392K
CYTK icon
44
Cytokinetics
CYTK
$10.9B
$446K 0.15%
9,211
-2,327
-20% -$112K
MOR
45
DELISTED
MorphoSys AG American Depositary Shares
MOR
$344K 0.11%
+68,290
New +$353K
BDSX icon
46
Biodesix
BDSX
$229M
$165K 0.05%
6,507
-31
-0.5% -$1.2K
ATNX
47
DELISTED
Athenex, Inc. Common Stock
ATNX
$142K 0.05%
+26,333
New +$271K
ACHC icon
48
Acadia Healthcare
ACHC
$2.87B
– –
-16,189
Closed -$1.09M
ADCT icon
49
ADC Therapeutics
ADCT
$140M
– –
-58,967
Closed -$469K
AXSM icon
50
Axsome Therapeutics
AXSM
$11B
– –
-15,246
Closed -$584K
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Endurant Capital Management held 71 positions worth $307M, up 7.7% from $285M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Endurant Capital Management deployed $44.8M of net new capital in Q3 2022, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Takeda Pharmaceutical: 1,102,280 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 70% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Avantor, an estimated $10M trimmed.

  • Endurant Capital Management's largest Q3 2022 buy was Takeda Pharmaceutical: 1,102,280 shares worth $14.3M.
  • Endurant Capital Management added most to Labcorp in Q3 2022, an estimated $14.9M increase.
  • Endurant Capital Management's biggest Q3 2022 reduction was Avantor, cutting an estimated $10M.
  • Endurant Capital Management fully exited Boston Scientific in Q3 2022, selling an estimated $15.6M.
  • Endurant Capital Management's ten largest holdings make up 56% of its $307M portfolio in Q3 2022.
  • Endurant Capital Management opened 21 new positions and closed 22 in Q3 2022.
  • Endurant Capital Management's portfolio value rose 7.7% quarter-over-quarter to $307M.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.